Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:00:34.342Z.
Consensus retrieved: 2026-10-06T08:20:46.791Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:00:34.342Z.
Quote observation: 2026-10-06T16:00:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c295c1623f78bdf77a886cf07ea1e6d336f06da24b8c95eb76ef4971c7c9c79e
Forward PE Ratio (N/A) = Dated Quote Price ($7.20) / Consensus Forward EPS ($-1.46)
FORWARD PE RATIO
N/A
Achieve Life Sciences, Inc.
Market Cap
$738.63M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Achieve Life Sciences, Inc. (ACHV) | $738.63M | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $746.62M | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $725.14M | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $752.35M | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $723.66M | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $719.02M | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $712.76M | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $764.79M | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $778.67M | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $778.76M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $7.20, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.46 | $-1.56 – $-1.35 | 8 | n/m |
| 2027-12-31 | $-0.68 | $-0.99 – $-0.24 | 9 | n/m |
| 2028-12-31 | $0.10 | $-0.30 – $0.86 | 8 | 68.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
